MedTrace Logo

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

NCT05287308 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2022-03-31

No results posted yet for this study

Summary

This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.

Conditions

Interventions

DRUG

doxorubicin

doxorubicin 50\~60mg/m2, i.v., d1, q3w or q2w.

DRUG

epirubicin

epirubicin 80\~100mg/m2, i.v., d1, q3w or q2w.

DRUG

pirarubicin

pirarubicin 40\~50mg/m2, i.v., d1, q3w or q2w.

DRUG

cyclophosphamide

cyclophosphamide 600mg/m2, i.v., d1, q3w or q2w.

DRUG

albumin-bound paclitaxel

albumin-bound paclitaxel 260mg/m2, i.v., d1, q3w; 260mg/m2, i.v., d1, q2w; or 125mg/m2, i.v., d1, qw.

DRUG

paclitaxel

paclitaxel 175mg/m2, i.v., d1, q3w; 175mg/m2, i.v., d1, q2w; or 80mg/m2, i.v., d1, qw.

DRUG

docetaxel

docetaxel 80\~100mg/m2, i.v., d1, q3w.

Sponsors & Collaborators

  • CSPC Ouyi Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Chinese Academy of Medical Sciences

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-31
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05287308 on ClinicalTrials.gov